<DOC>
	<DOCNO>NCT01378611</DOCNO>
	<brief_summary>Clinical randomize control observer blind add-on design . Additionally non-controlled follow-up phase study . Children ( Age 4-18 year ) intractable epilepsy , eligible resective surgery treat VNS . Aim study : 1 . To evaluate tolerability effectiveness VNS child intractable epilepsy cognitive behavioural problem control study . 2 . To evaluate effect VNS immune system , turn , lead change serotonin metabolic pathway 3 . To link therapeutic effect VNS change serotonin ( 5HT ) metabolic pathway . In addition investigator hope detect marker immune neurotransmitter function enable u predict 1 ) Neuronal cell loss relation cognitive decline 2 ) response therapeutic treatment VNS . Hypothesis : The investigator aim explore neuronal correlate cognitive morbidity child intractable epilepsy relate morphologic change , biochemical marker , epilepsy characteristic . Correction `` stress '' pro-inflammatory status monocytes/macrophages via electrical stimulation vagus nerve prevent/ameliorate seizure well behavioural mood symptom child refractory epilepsy , characterize `` pro-inflammatory monocyte signature ''</brief_summary>
	<brief_title>Does VNS Interact With Serotonergic Immune System Children With Intractable Epilepsy ?</brief_title>
	<detailed_description>Background information : Repetitive seizure lead increase pro-inflammatory cytokine peripheral blood . Experimentally show activation inflammatory cytokine peripheral administration toxic agent cause sickness behaviour . Pro-inflammatory cytokine interfere catabolisation precursor Serotonin ( Tryptophan ) . Tryptophan catabolise endogen NMDA receptor agonist . NMDA ( excitatory neurotransmitter ) lead neuronal damage . The Vagus Nerve ( VN ) play important role interaction neurotransmitter immune system cytokine crucial . Vagus nerve stimulation ( VNS ) effect various amino-acid pool brain . Patients respond VNS show significantly increase serotonin metabolites cerebrospinal fluid . VNS also associate marked peripheral increase pro- , anti-inflammatory circulating cytokine . Given complexity serotonergic system interaction multiple neurotransmitter system human brain surprising find serotonin play role etiology course affective disorder . It expect serotonin-immune pathway also play role course epilepsy . Study population : Children ( Age 4-18 year ) intractable epilepsy , eligible resective surgery Study design : Clinical randomized control observer blind add-on design . Additionally , non-controlled follow-up study , active control group receive therapeutic stimulation parameter . In secondary analysis VNS group compare pre-surgical period ( baseline ) Intervention : VNS The generator implant beneath subcutaneous tissue upper chest region . The electrode tunnel generator stimulation site neck . The system program computer . The pulse width , output current , signal frequency stimulation time program telemetrically . The study group stimulate follow parameter : Output current 0.25 milliampere ( ramp max . 1.75 milliampere ) , Pulse width 0.5 millisecond , Frequency 30 Hz , Duty cycle : 30 sec 5 min ( duty cycle 10 % ) . The active control group stimulate : Output current 0.25 milliampere , Pulse width 0.1 millisecond , Frequency 1 Hz , Duty cycle : 14 sec 60 min ( duty cycle &lt; 0.5 % ) Primary endpoint : Seizure frequency reduction 50 % . Main variable : Demographics Epilepsy specific data ( Seizure frequency ( diary ) , Medication ) Biochemical neuro-immunological assessment peripheral blood CSF ( serotonin metabolite , Noradrenalin , GABA , Glutamate , pro- , anti-inflammatory cytokine ) . Neuropsychologic variable ( mood , cognition , QoL )</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>Seizures adequately control antiepileptic drug first second choice adequate stable serum anticonvulsant concentration Acceptable seizure regulation intolerable side effect adequate stable serum anticonvulsant concentration Not eligible epilepsy surgery Age 4 18 year Informed consent Evidence progressive cerebral lesion , degenerative disorder , malignancy history malignancy past 5 year Unstable medical disease ( i.e . cardiovascular , hepatic , renal , musculoskeletal , gastrointestinal , metabolic , endocrine ) last 2 year Documented history generalize status epilepticus past three month High risk complication ( obstructive respiratory disease , gastric disorder , cardiac I disorder ) A history alcohol drug abuse , psychiatric disorder require electroconvulsive therapy , chronic use major tranquilliser ( neuroleptic , antidepressant , MAO inhibitor ) past 6 month Regularly treatment antihistamine , metoclopramide CNSactive compound Treatment experimental drug past 30 day Subjects schizophrenic exhibit psychotic symptomatology</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>intractable childhood epilepsy</keyword>
	<keyword>VNS</keyword>
	<keyword>immune system</keyword>
</DOC>